SUPN — Supernus Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $2.91bn
- $2.60bn
- $718.95m
Annual cashflow statement for Supernus Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 53.4 | 60.7 | 1.32 | 73.9 | -38.5 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 42.5 | 19 | 59.8 | 39.9 | 64.3 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.57 | -22.1 | -9.14 | -2.05 | -75.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | 127 | 117 | 111 | 172 | 47.3 |
| Capital Expenditures | -2.04 | -0.412 | -0.551 | -0.725 | -1.34 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -79.9 | -216 | 269 | -189 | 5.44 |
| Acquisition of Business | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -81.9 | -217 | 269 | -190 | 4.11 |
| Financing Cash Flow Items | — | -22.9 | -1.99 | -2.71 | -28.5 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -130 | -10.5 | -398 | 12.2 | 9.13 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -85.2 | -110 | -18.1 | -5.72 | 60.6 |